iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer

June 17, 2014 iBio, Inc., a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil’s Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunchâ„¢-produced recombinant yellow fever vaccine and other products. Yellow fever vaccine candidates based on iBio’s proprietary technology, …

iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology

April 24, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines. “The invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins,” said Dr. Wayne Fitzmaurice, iBio’s vice-president of …

iBio Receives Patent Allowances for Pandemic Influenza Therapeutics

March 27, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza. “The antibodies covered by these patents are designed to block critical functions of the influenza virus necessary for infection or replication,” said Wayne P. Fitzmaurice, Ph.D., iBio’s vice president of intellectual property. …

Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio’s Proprietary Technology

February 10th, 2014 iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company’s proprietary iBioLaunchâ„¢ platform by the Fraunhofer USA Center for Molecular Biotechnology. The text describing the program, released …